Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients

被引：40

作者：

Song, Tae-Jin ^{[1
]}

Kim, Jinkwon ^{[1
]}

Yang, Seung-Hee ^{[1
,2
]}

Park, Ji Hye ^{[1
]}

Lee, Hye Sun

Nam, Chung Mo ^{[3
]}

Lee, Ok-Hee ^{[2
]}

Kim, Young Dae ^{[2
]}

Nam, Hyo Suk ^{[1
]}

Heo, Ji Hoe ^{[1
,2
]}

机构：

[1] Yonsei Univ, Coll Med, Dept Neurol, Seoul 120752, South Korea

[2] Yonsei Univ, Coll Med, Severance Cerebral & Cardiovasc Integrat Res Inst, Seoul 120752, South Korea

[3] Yonsei Univ, Coll Med, Dept Biostat, Seoul 120752, South Korea

来源：

BIOMARKERS | 2012年 / 17卷 / 08期

关键词：

Stroke; osteoprotegerin; functional outcome; stroke severity; NF-KAPPA-B; SERUM OSTEOPROTEGERIN; ENDOTHELIAL-CELLS; LIGAND; CALCIFICATION; PROGNOSIS; MORTALITY; SUBTYPE; DISEASE; RISK;

D O I：

10.3109/1354750X.2012.727027

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Osteoprotegerin (OPG) is known to regulate processes involved in vascular injury and inflammation. We investigated the relationship between plasma OPG levels and stroke subtype, stroke severity at admission and functional outcome at 3 months in 172 patients with acute ischaemic stroke. Patients with large artery atherosclerosis and those with multiple causes had higher plasma OPG levels than patients with lacune. Increased plasma OPG levels were independently associated with more severe stroke and poor functional outcome. These results suggest pleiotropic roles of OPG in mediating atherosclerosis and ischaemic brain injury. OPG is a potential biomarker for predicting neurologic outcome in stroke.

引用

页码：738 / 744

页数：7

共 30 条

[1] CLASSIFICATION OF SUBTYPE OF ACUTE ISCHEMIC STROKE - DEFINITIONS FOR USE IN A MULTICENTER CLINICAL-TRIAL [J].

ADAMS, HP ;

BENDIXEN, BH ;

KAPPELLE, LJ ;

BILLER, J ;

LOVE, BB ;

GORDON, DL ;

MARSH, EE ;

KASE, CS ;

WOLF, PA ;

BABIKIAN, VL ;

LICATAGEHR, EE ;

ALLEN, N ;

BRASS, LM ;

FAYAD, PB ;

PAVALKIS, FJ ;

WEINBERGER, JM ;

TUHRIM, S ;

RUDOLPH, SH ;

HOROWITZ, DR ;

BITTON, A ;

MOHR, JP ;

SACCO, RL ;

CLAVIJO, M ;

ROSENBAUM, DM ;

SPARR, SA ;

KATZ, P ;

KLONOWSKI, E ;

CULEBRAS, A ;

CAREY, G ;

MARTIR, NI ;

FICARRA, C ;

HOGAN, EL ;

CARTER, T ;

GURECKI, P ;

MUNTZ, BK ;

RAMIREZLASSEPAS, M ;

TULLOCH, JW ;

QUINONES, MR ;

MENDEZ, M ;

ZHANG, SM ;

ALA, T ;

JOHNSTON, KC ;

ANDERSON, DC ;

TARREL, RM ;

NANCE, MA ;

BUDLIE, SR ;

DIERICH, M ;

HELGASON, CM ;

HIER, DB ;

SHAPIRO, RA .

STROKE, 1993, 24 (01) :35-41

[2]

American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5

[3] ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly [J].

Aronow, Wilbert S. ;

Fleg, Jerome L. ;

Pepine, Carl J. ;

Artinian, Nancy T. ;

Bakris, George ;

Brown, Alan S. ;

Ferdinand, Keith C. ;

Forciea, Mary Ann ;

Frishman, William H. ;

Jaigobin, Cheryl ;

Kostis, John B. ;

Mancia, Giuseppi ;

Oparil, Suzanne ;

Ortiz, Eduardo ;

Reisin, Efrain ;

Rich, Michael W. ;

Schocken, Douglas D. ;

Weber, Michael A. ;

Wesley, Deborah J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (20) :2037-2114

[4] Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice [J].

Bennett, Brian J. ;

Scatena, Marta ;

Kirk, Elizabeth A. ;

Rattazzi, Marcello ;

Varon, Rebecca M. ;

Averill, Michelle ;

Schwartz, Stephen M. ;

Giachelli, Cecilia M. ;

Rosenfeld, Michael E. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (09) :2117-2124

[5] Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women [J].

Browner, WS ;

Lui, LY ;

Cummings, SR .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :631-637

[6] Three-year survival after first-ever ischemic stroke is predicted by initial stroke severity: A hospital-based study [J].

Chang, Ku-Chou ;

Lee, Hsuei-Chen ;

Tseng, Mei-Chiun ;

Huang, Yu-Ching .

CLINICAL NEUROLOGY AND NEUROSURGERY, 2010, 112 (04) :296-301

[7] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

[8] Statins decrease TNF-α-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro [J].

Cohen, E. Ben-Tal ;

Hohensinner, P. J. ;

Kaun, C. ;

Maurer, G. ;

Huber, K. ;

Wojta, J. .

BIOCHEMICAL PHARMACOLOGY, 2007, 73 (01) :77-83

[9] Functional outcome 3 months after stroke predicts long-term survival [J].

Eriksson, Marie ;

Norrving, Bo ;

Terent, Andreas ;

Stegmayr, Birgitta .

CEREBROVASCULAR DISEASES, 2008, 25 (05) :423-429

[10] Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis [J].

Golledge, J ;

McCann, M ;

Mangan, S ;

Lam, A ;

Karan, M .

STROKE, 2004, 35 (07) :1636-1641

← 1 2 3 →